Thursday, April 7, 2016

BRIEF-Durect says will implement changes to Persist phase 3 trials advised by FDA

* After persist phase 3 trial for posimir was underway and

enrolling patients at multiple sites, co received a letter from

FDA - sec filing

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)